<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375165</url>
  </required_header>
  <id_info>
    <org_study_id>17690</org_study_id>
    <nct_id>NCT02375165</nct_id>
  </id_info>
  <brief_title>Biomarkers for the Detection of Lymphatic Insufficiency</brief_title>
  <acronym>Biomarkers</acronym>
  <official_title>Biomarkers for the Detection of Lymphatic Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acquired lymphedema is a disease that causes chronic swelling of the limb(s). It is&#xD;
      frequently under-recognized or misdiagnosed. This study is designed to lead to the&#xD;
      development of an accurate, noninvasive, blood test to allow testing for lymphedema. This&#xD;
      approach is particularly useful to investigate relative responses to treatment interventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The validation of a sensitive and specific biomarker assay for human acquired lymphatic&#xD;
      vascular insufficiency would represent a highly significant development for the patient&#xD;
      community. Accurate bioassay for the presence of lymphatic vascular insufficiency should help&#xD;
      to pave the road for future human clinical trials of experimental drugs and therapies&#xD;
      designed to treat human lymphatic diseases. Molecular profiling will be performed in human&#xD;
      tissues (skin) obtained by biopsy. The insights gained from these initial analyses will&#xD;
      determine the targets for assay in human body fluids (blood).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers for the Detection of Lymphatic Vascular Insufficiency</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Cohort with lymphedema</arm_group_label>
    <description>Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort without lymphedema</arm_group_label>
    <description>Healthy volunteers; will have phlebotomy for serum and plasma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>phlebotomy</intervention_name>
    <description>phlebotomy for collection of plasma and serum, ~30 cc</description>
    <arm_group_label>Cohort with lymphedema</arm_group_label>
    <arm_group_label>Cohort without lymphedema</arm_group_label>
    <other_name>venipuncture</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who receive their care within Dr. Rockson's clinic in the Stanford Center for&#xD;
        Lymphatic and Venous Disorders may be spoken to about voluntary participation in this&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        For lymphedema participants:&#xD;
&#xD;
          -  clinical diagnosis of lymphedema of at least 6 months' duration&#xD;
&#xD;
        Control participants:&#xD;
&#xD;
          -  no evidence of lymphedema&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        For lymphedema participants:&#xD;
&#xD;
          -  active cancer&#xD;
&#xD;
          -  infection&#xD;
&#xD;
          -  bleeding tendency&#xD;
&#xD;
          -  active coronary artery disease&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  history of stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  renal insufficiency (serum creatinine &gt; 1.1)&#xD;
&#xD;
          -  active inflammatory or autoimmune disease (other than lymphedema)&#xD;
&#xD;
        For control participants:&#xD;
&#xD;
          -  lymph node dissection&#xD;
&#xD;
          -  radiation therapy&#xD;
&#xD;
          -  active inflammatory disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley G Rockson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2015</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Stanley Rockson</investigator_full_name>
    <investigator_title>Allan and Tina Neill Professor of Lymphatic Research and Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>to be determined</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Available one year after the last study visit and for one year duration.</ipd_time_frame>
    <ipd_access_criteria>Requestors will be required to complete a Data Access Agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

